Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
NCT ID: NCT00195507
Last Updated: 2013-02-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
720 participants
INTERVENTIONAL
2004-12-31
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
NCT00161655
Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis
NCT00116181
Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy
NCT00581555
An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis
NCT00111111
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
NCT01241591
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etanercept
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failure to respond to the following systemic therapies: Methotrexate, Cyclosporine, PUVA or Fumarate
Exclusion Criteria
* Systemic psoriasis therapy within 28 days prior
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Feldkirch, , Austria
Vienna, , Austria
Vienna, , Austria
Brussels, , Belgium
Brussels, , Belgium
Edegem, , Belgium
Ghent, , Belgium
Leuven, , Belgium
Liège, , Belgium
Prague, , Czechia
Aarhus C, , Denmark
Odense C, , Denmark
Roskilde, , Denmark
Kuopio, , Finland
Lahti, , Finland
Besançon, , France
Bordeaux, , France
Boulogne-Billancourt, , France
Brest, , France
Créteil, , France
Dijon, , France
Lille, , France
Lyon, , France
Lyon, , France
Marseille, , France
Marseille Cédex 09, , France
Montpellier Cédex 5, , France
Nancy, , France
Nantes, , France
Nice, , France
Nîmes, , France
Paris, , France
Pessac, , France
Pierre-Bénite, , France
Poitiers, , France
Reims, , France
Rouen, , France
Saint-Etienne, , France
Strasbourg, , France
Toulouse, , France
Tours, , France
Bochum, , Germany
Düsseldorf, , Germany
Erlangen, , Germany
Essen, , Germany
Frankfurt, , Germany
Hamburg, , Germany
Kiel, , Germany
Leipzig, , Germany
Magdeburg, , Germany
Mainz, , Germany
Münster, , Germany
Nordheide, , Germany
Osnabrück, , Germany
Tübingen, , Germany
Würzburg, , Germany
Athens, , Greece
Athens, , Greece
Thessaloniki, , Greece
Budapest, , Hungary
Ancona, , Italy
Cagliari, , Italy
Genova, , Italy
Modena, , Italy
Padua, , Italy
Pavia, , Italy
Roma, , Italy
Roma, , Italy
Roma, , Italy
Terni, , Italy
Torino, , Italy
Amsterdam, , Netherlands
Amsterdam, , Netherlands
Capelle aan den IJssel, , Netherlands
Heerlen, , Netherlands
Nijmegen, , Netherlands
Rotterdam, , Netherlands
Utrecht, , Netherlands
Voorburg, , Netherlands
Bergen, , Norway
Oslo, , Norway
Stavanger, , Norway
Warsaw, , Poland
Lisbon, , Portugal
Lisbon, , Portugal
Barcelona, , Spain
Bilbao, , Spain
Llobregat, , Spain
Madrid, , Spain
Madrid, , Spain
Madrid, , Spain
Málaga, , Spain
Valencia, , Spain
Danderyds, , Sweden
Gothenburg, , Sweden
Linköping, , Sweden
Lund, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Basel, , Switzerland
Bern, , Switzerland
Geneva, , Switzerland
Bornova-Izmir, , Turkey (Türkiye)
Capa-Istanbul, , Turkey (Türkiye)
Kocamustafapasa-Istanbul, , Turkey (Türkiye)
Aberdeen, , United Kingdom
Airdrie, , United Kingdom
Birmingham, , United Kingdom
Cardiff, , United Kingdom
Coventry, , United Kingdom
Dublin, , United Kingdom
Dundee, , United Kingdom
Glasgow, , United Kingdom
Lancaster, , United Kingdom
Leeds, , United Kingdom
Leicester, , United Kingdom
Liverpool, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Newcastle upon Tyne, , United Kingdom
Newport, , United Kingdom
Norwich, , United Kingdom
Salford, , United Kingdom
Sheffield, , United Kingdom
Suffolk, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Griffiths CE, Christophers E, Szumski A, Jones H, Mallbris L. Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. Br J Dermatol. 2015 Nov;173(5):1271-3. doi: 10.1111/bjd.13865. Epub 2015 Aug 17. No abstract available.
Griffiths CE, Luger TA, Brault Y, Germain JM, Mallbris L. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):468-73. doi: 10.1111/jdv.12585. Epub 2014 Aug 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0881A6-101764
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.